0000899243-20-032449.txt : 20201202
0000899243-20-032449.hdr.sgml : 20201202
20201202094507
ACCESSION NUMBER: 0000899243-20-032449
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201202
FILED AS OF DATE: 20201202
DATE AS OF CHANGE: 20201202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sherman Michael A.
CENTRAL INDEX KEY: 0001509463
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34236
FILM NUMBER: 201362574
MAIL ADDRESS:
STREET 1: 3000 KENT AVE STE A1-100
CITY: WEST LAFAYETTE
STATE: IN
ZIP: 47906
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0000875622
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113054851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 WILBUR ST
CITY: LYNBROOK
STATE: NY
ZIP: 11563
BUSINESS PHONE: 302-842-8450
MAIL ADDRESS:
STREET 1: 2 RIGHTER PARKWAY, SUITE 200
CITY: WILMINGTON
STATE: DE
ZIP: 19803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-02
1
0000875622
BIOSPECIFICS TECHNOLOGIES CORP
BSTC
0001509463
Sherman Michael A.
C/O BIOSPECIFICS TECHNOLOGIES CORP.
2 RIGHTER PKWY, DE CORP CENTER II
WILMINGTON
DE
19803
1
0
0
0
Common Stock, $0.001 par value
2020-12-02
4
D
0
2018
D
0
D
Stock Option (Right to Buy)
55.63
2020-12-02
4
D
0
6000
32.87
D
2030-05-01
Common Stock
6000
0
D
Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 2,018 outstanding restricted stock units ("RSUs") were canceled in exchange for a cash payment of $178,593.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50).
Upon the consummation of the Merger, pursuant to the Merger Agreement, the stock options, which provided for vesting in three equal annual installments following the grant date (May 1, 2020), were canceled in exchange for a cash payment of $197,220.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.
/s/ Michael Sherman by Carl A. Valenstein, attorney-in-fact
2020-12-02